Trial reportBMC psychiatry2025
Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China.
Trial report in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis clinical pilot initiative, led by the Sichuan Provincial Government in western China, aims to develop an innovative model for "integrated hospital-community management and treatment of severe mental disorders" to enhance the management of patients with such conditions. This single-arm, open-label, prospective, multicenter, interventional study was designed to evaluate the efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) in patients with schizophrenia.
methodsThe study enrolled patients with schizophrenia aged 18-55 from all 21 prefectural-level municipalities in Sichuan Province, southwestern China, who received PP1M at doses of 75, 100, or 150 mg. Efficacy and social functioning were assessed using the PANSS and SDSS scales at baseline and after the 3rd, 6th, and 9th injections. The SF-12 scale was administered at baseline and at 6 months, while satisfaction (MSQ) was measured at 1, 3, 6, and 9 months. The TESS scale was performed at the 1st, 3rd, 6th, and 9th doses, with adverse events (AEs) monitored after the 1st, 2nd, 3rd, and 9th doses to evaluate safety.
resultsA total of 2268 patients were enrolled, with 1491 completing the 9th injection. The numbers of patients completing the PANSS, SDSS, SF-12, MSQ, and TESS scales were 1151, 1158, 1043, 827, and 1158, respectively. Following multiple PP1M doses, total PANSS scores, positive symptom subscale scores, negative symptom subscale scores, general psychopathological subscale scores, and SDSS scores significantly decreased compared to baseline (P < 0.05), while SF-12 and MSQ scores significantly increased (P < 0.05). The PANSS total response rates were 64.90% (747/1151), 74.63% (859/1151), and 78.71% (906/1151) after the 3rd, 6th, and 9th injections, respectively. TESS scores significantly decreased compared to the first injection (P < 0.05), reflecting a lower incidence of AEs. Common adverse reactions, including tremors, muscle tension, dizziness, and fatigue, were mild to moderate in severity.
conclusionsThese findings indicate that PP1M significantly alleviates psychotic symptoms in patients with schizophrenia, accelerates social function recovery, and improves quality of life and patient satisfaction. Furthermore, PP1M demonstrates improved tolerability, fewer adverse reactions, and no new drug-related safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.